Ahmed S, Alam W, Jeandet P, Aschner M, Alsharif KF, Saso L, Khan H (2022) Therapeutic potential of marine peptides in prostate cancer: mechanistic insights. Marine Drugs 20(8):466

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed S, Alam W, Aschner M, Filosa R, Cheang WS, Jeandet P, Khan H (2023) Marine cyanobacterial peptides in neuroblastoma: Search for better therapeutic options. Cancers 15(9):2515

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmed S, Alam W, Alsharif KF, Aschner M, Alzahrani FM, Saso L, Khan H (2023a) Therapeutic potential of marine peptides in malignant melanoma. Environ Res 227:115771

Article  CAS  PubMed  Google Scholar 

Ahmed S, Alam W, Aschner M, Filosa R, Cheang WS, Jeandet P, Saso L, Khan H (2023b) Marine cyanobacterial peptides in neuroblastoma: search for better therapeutic options. Cancers (Basel) 15(9):2515

Article  CAS  PubMed  Google Scholar 

Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Khan K, Atkins L, Rada A, Kim HA, Chiuzan C, Kalac M, Marchi E, Falchi L, Francescone MA, Schwartz L, Cremers S, O’Connor OA (2018) A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 131(4):397–407

Article  CAS  PubMed  PubMed Central  Google Scholar 

Angirish B, Sanghavi P, Jankharia B (2020) Pulmonary manifestations of lymphoma: A pictorial essay. Lung India 37(3):263–267

Article  PubMed  PubMed Central  Google Scholar 

Anson F, Thayumanavan S, Hardy JA (2021) Exogenous Introduction of Initiator and Executioner Caspases Results in Different Apoptotic Outcomes. JACS Au 1(8):1240–1256

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aspeslagh S, Stein M, Bahleda R, Hollebecque A, Salles G, Gyan E, Fudio S, Extremera S, Alfaro V, Soto-Matos A, Soria J-C (2017) Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas. Anti-Cancer Drugs 28(3):341–349

Article  CAS  PubMed  Google Scholar 

Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R-O, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue M-H, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R (2021) Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol 40(3):242–251

Article  PubMed  Google Scholar 

Bai R, Friedman SJ, Pettit GR, Hamel E (1992) Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia: Interaction with tubulin and effects on cellular microtubules. Biochem Pharmacol 43(12):2637–2645

Article  CAS  PubMed  Google Scholar 

Barboza NM, Medina DJ, Budak-Alpdogan T, Aracil M, Jimeno JM, Bertino JR, Banerjee D (2012) Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biol Ther 13(2):114–122

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barreca M, Spanò V, Montalbano A, Cueto M, Díaz Marrero AR, Deniz I, Erdoğan A, Lukić Bilela L, Moulin C, Taffin-de-Givenchy E (2020a) Marine anticancer agents: An overview with a particular focus on their chemical classes. Marine Drugs 18(12):619

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barreca M, Stathis A, Barraja P, Bertoni F (2020b) An overview on anti-tubulin agents for the treatment of lymphoma patients. Pharmacol Ther 211:107552

Article  CAS  PubMed  Google Scholar 

Bates D, Eastman A (2017) Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Br J Clin Pharmacol 83(2):255–268

Article  CAS  PubMed  Google Scholar 

Beckwith M, Urba WJ, Longo DL (1993) Growth Inhibition of Human Lymphoma Cell Lines by the Marine Products, Dolastatins 10 and 15. JNCI: J Nat Cancer Institute 85(6):483–488

Article  CAS  Google Scholar 

Bispo JAB, Pinheiro PS, Kobetz EK (2020) Epidemiology and Etiology of Leukemia and Lymphoma. Cold Spring Harb Perspect Med 10(6):a034819

Article  PubMed  PubMed Central  Google Scholar 

Bröckelmann PJ, de Jong MRW, Jachimowicz RD (2020) Targeting DNA repair, cell cycle, and Tumor microenvironment in B cell lymphoma. Cells 9(10):2287

Article  PubMed  PubMed Central  Google Scholar 

Brucoli F, Natoli A, Marimuthu P, Borrello MT, Stapleton P, Gibbons S, Schätzlein A (2012) Efficient synthesis and biological evaluation of proximicins A, B and C. Bioorg Med Chem 20(6):2019–2024

Article  CAS  PubMed  Google Scholar 

Chaudhry GES, Md Akim A, Sung YY, Sifzizul TMT (2022) Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics. Front Pharmacol 13:842376

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen IC, Sethy B, Liou JP (2020) Recent Update of HDAC Inhibitors in Lymphoma. Front Cell Dev Biol 8:576391

Article  PubMed  PubMed Central  Google Scholar 

Cheng-Sánchez I, Moya-Utrera F, Porras-Alcalá C, López-Romero JM, Sarabia F (2022) Antibody-drug conjugates containing payloads from marine origin. Marine Drugs 20(8):494

Article  PubMed  PubMed Central  Google Scholar 

Chiangjong W, Chutipongtanate S, Hongeng S (2020) Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application. Int J Oncol 57(3):678–696

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chihara D, Oki Y, Fayad L, Wesson E, Ruben C, Horowitz SB, Woolery J, Feng L, Garg N, Ahmed S, Khouri IF, Fanale MA (2014) Phase I Study of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood 124(21):1748–1748

Article  Google Scholar 

Chinnadurai RK, Khan N, Meghwanshi GK, Ponne S, Althobiti M, Kumar R (2023) Current research status of anti-cancer peptides: Mechanism of action, production, and clinical applications. Biomed Pharmacother 164:114996

Article  CAS  PubMed  Google Scholar 

Cho Y, Park MN, Noh S, Kang SY, Kim B (2020) Review of Natural Compounds for the Management and Prevention of Lymphoma. Processes 8(9):1164

Article  CAS  Google Scholar 

Chu Y, Zhou X, Wang X (2021) Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J Hematol Oncol 14(1):88

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chu Y, Liu Y, Fang X, Jiang Y, Ding M, Ge X, Yuan D, Lu K, Li P, Li Y, Xu H, Fan J, Zhou X, Wang X (2022) Global Burden, Risk Factors, and Trends of Non-Hodgkin Lymphoma in 2020 and Projections to 2040: A Population-Based Study. Blood 140(Supplement 1):3844–3845

Article  Google Scholar 

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 378(4):331–344

Article  CAS  PubMed  Google Scholar 

Cosenza M, Civallero M, Fiorcari S, Pozzi S, Marcheselli L, Liardo EV, Bari A, Sacchi S (2013) Romidepsin and lenalidomide show a synergistic effect In T-Cell lymphoma cell lines. Blood 122(21):5148

Article  Google Scholar 

Cosenza M, Civallero M, Fiorcari S, Pozzi S, Marcheselli L, Bari A, Ferri P, Sacchi S (2016) The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines. Cancer Biol Ther 17(10):1094–1106

Article  CAS